Annual Accounts Receivable
$12.97 B
+$4.57 B+54.30%
December 1, 2024
Summary
- As of February 7, 2025, AZN annual accounts receivable is $12.97 billion, with the most recent change of +$4.57 billion (+54.30%) on December 1, 2024.
- During the last 3 years, AZN annual accounts receivable has risen by +$6.94 billion (+115.09%).
- AZN annual accounts receivable is now at all-time high.
Performance
AZN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$11.88 B
+$832.00 M+7.53%
September 30, 2024
Summary
- As of February 7, 2025, AZN quarterly accounts receivable is $11.88 billion, with the most recent change of +$832.00 million (+7.53%) on September 30, 2024.
- Over the past year, AZN quarterly accounts receivable has increased by +$579.00 million (+5.12%).
- AZN quarterly accounts receivable is now at all-time high.
Performance
AZN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
AZN Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +54.3% | +5.1% |
| 3 y3 years | +115.1% | +33.4% |
| 5 y5 years | +261.8% | +33.4% |
AZN Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +115.1% | at high | +97.0% |
| 5 y | 5-year | at high | +261.8% | at high | +231.3% |
| alltime | all time | at high | +896.8% | at high | +6391.3% |
AstraZeneca Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $12.97 B(+54.3%) | - |
| Sep 2024 | - | $11.88 B(+7.5%) |
| Jun 2024 | - | $11.05 B(-0.2%) |
| Mar 2024 | - | $11.07 B(+31.7%) |
| Dec 2023 | $8.41 B(+16.6%) | $8.41 B(-25.6%) |
| Sep 2023 | - | $11.30 B(+1.9%) |
| Jun 2023 | - | $11.09 B(+7.8%) |
| Mar 2023 | - | $10.29 B(+42.7%) |
| Dec 2022 | $7.21 B(+19.6%) | $7.21 B(-22.8%) |
| Sep 2022 | - | $9.34 B(+4.8%) |
| Jun 2022 | - | $8.91 B(+2.6%) |
| Mar 2022 | - | $8.68 B(+44.0%) |
| Dec 2021 | $6.03 B(+58.5%) | $6.03 B(-27.0%) |
| Sep 2021 | - | $8.26 B(+29.9%) |
| Jun 2021 | - | $6.36 B(+1.2%) |
| Mar 2021 | - | $6.28 B(+65.0%) |
| Dec 2020 | $3.81 B(+6.2%) | $3.81 B(-32.9%) |
| Sep 2020 | - | $5.67 B(+12.8%) |
| Jun 2020 | - | $5.02 B(-1.1%) |
| Mar 2020 | - | $5.08 B(+41.7%) |
| Dec 2019 | $3.58 B(+19.7%) | $3.58 B(-32.1%) |
| Sep 2019 | - | $5.28 B(-0.8%) |
| Jun 2019 | - | $5.32 B(+0.6%) |
| Mar 2019 | - | $5.29 B(+76.6%) |
| Dec 2018 | $3.00 B(+6.9%) | $3.00 B(-45.6%) |
| Sep 2018 | - | $5.51 B(+4.8%) |
| Jun 2018 | - | $5.26 B(-3.4%) |
| Mar 2018 | - | $5.44 B(+94.3%) |
| Dec 2017 | $2.80 B(+8.5%) | $2.80 B(-38.3%) |
| Sep 2017 | - | $4.54 B(+4.4%) |
| Jun 2017 | - | $4.35 B(-7.2%) |
| Mar 2017 | - | $4.69 B(+81.4%) |
| Dec 2016 | $2.58 B(-44.2%) | $2.58 B(-52.6%) |
| Sep 2016 | - | $5.45 B(-3.0%) |
| Jun 2016 | - | $5.62 B(-4.2%) |
| Mar 2016 | - | $5.87 B(+26.6%) |
| Dec 2015 | $4.63 B(-2.7%) | $4.63 B(-21.2%) |
| Sep 2015 | - | $5.88 B(-11.2%) |
| Jun 2015 | - | $6.62 B(-1.3%) |
| Mar 2015 | - | $6.70 B(+40.8%) |
| Dec 2014 | $4.76 B(-13.6%) | $4.76 B(-30.1%) |
| Sep 2014 | - | $6.81 B(-12.9%) |
| Jun 2014 | - | $7.82 B(-8.9%) |
| Mar 2014 | - | $8.58 B(+55.6%) |
| Dec 2013 | $5.51 B | $5.51 B(-24.4%) |
| Sep 2013 | - | $7.29 B(+0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $7.27 B(-3.4%) |
| Mar 2013 | - | $7.52 B(+32.0%) |
| Dec 2012 | $5.70 B(-14.1%) | $5.70 B(-28.8%) |
| Sep 2012 | - | $8.00 B(+7.2%) |
| Jun 2012 | - | $7.46 B(-12.3%) |
| Mar 2012 | - | $8.51 B(+28.4%) |
| Dec 2011 | $6.63 B(+6.1%) | $6.63 B(-20.2%) |
| Sep 2011 | - | $8.31 B(-0.1%) |
| Jun 2011 | - | $8.32 B(-2.0%) |
| Mar 2011 | - | $8.49 B(+36.0%) |
| Dec 2010 | $6.25 B(+8.0%) | $6.25 B(-19.2%) |
| Sep 2010 | - | $7.74 B(+5.9%) |
| Jun 2010 | - | $7.31 B(-10.1%) |
| Mar 2010 | - | $8.13 B(+40.5%) |
| Dec 2009 | $5.78 B(-20.4%) | $5.78 B(-27.8%) |
| Sep 2009 | - | $8.01 B(+8.8%) |
| Jun 2009 | - | $7.36 B(+3.3%) |
| Mar 2009 | - | $7.13 B(-1.9%) |
| Dec 2008 | $7.26 B(+36.3%) | $7.26 B(+1.1%) |
| Sep 2008 | - | $7.18 B(-2.1%) |
| Jun 2008 | - | $7.33 B(+4.0%) |
| Mar 2008 | - | $7.05 B(+32.4%) |
| Dec 2007 | $5.33 B(+24.2%) | $5.33 B(-18.0%) |
| Sep 2007 | - | $6.49 B(+3.7%) |
| Jun 2007 | - | $6.26 B(+0.4%) |
| Mar 2007 | - | $6.24 B(+45.5%) |
| Dec 2006 | $4.29 B(-10.3%) | $4.29 B(+558.7%) |
| Sep 2006 | - | $651.00 M(+138.5%) |
| Jun 2006 | - | $273.00 M(-94.3%) |
| Dec 2005 | $4.78 B(+33.1%) | $4.78 B(+2496.7%) |
| Sep 2005 | - | $184.00 M(-8.5%) |
| Jun 2005 | - | $201.00 M(+9.8%) |
| Mar 2005 | - | $183.00 M(-94.9%) |
| Dec 2004 | $3.59 B(+12.1%) | $3.59 B(-28.0%) |
| Sep 2004 | - | $4.99 B(+55.7%) |
| Dec 2003 | $3.20 B(+21.1%) | $3.20 B(+21.1%) |
| Dec 2002 | $2.65 B(+10.8%) | $2.65 B(+10.8%) |
| Dec 2001 | $2.39 B(-10.4%) | $2.39 B(-10.4%) |
| Dec 2000 | $2.66 B(+66.3%) | $2.66 B(+66.3%) |
| Dec 1997 | $1.60 B(+0.0%) | $1.60 B(+0.0%) |
| Dec 1996 | $1.60 B(+5.7%) | $1.60 B(+5.7%) |
| Dec 1995 | $1.51 B(+8.2%) | $1.51 B(+8.2%) |
| Dec 1994 | $1.40 B(-1.1%) | $1.40 B(-1.1%) |
| Dec 1993 | $1.41 B(+8.7%) | $1.41 B |
| Dec 1992 | $1.30 B(-10.8%) | - |
| Dec 1991 | $1.46 B(-10.7%) | - |
| Dec 1990 | $1.63 B | - |
FAQ
- What is AstraZeneca annual accounts receivable?
- What is the all time high annual accounts receivable for AstraZeneca?
- What is AstraZeneca annual accounts receivable year-on-year change?
- What is AstraZeneca quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for AstraZeneca?
- What is AstraZeneca quarterly accounts receivable year-on-year change?
What is AstraZeneca annual accounts receivable?
The current annual accounts receivable of AZN is $12.97 B
What is the all time high annual accounts receivable for AstraZeneca?
AstraZeneca all-time high annual accounts receivable is $12.97 B
What is AstraZeneca annual accounts receivable year-on-year change?
Over the past year, AZN annual accounts receivable has changed by +$4.57 B (+54.30%)
What is AstraZeneca quarterly accounts receivable?
The current quarterly accounts receivable of AZN is $11.88 B
What is the all time high quarterly accounts receivable for AstraZeneca?
AstraZeneca all-time high quarterly accounts receivable is $11.88 B
What is AstraZeneca quarterly accounts receivable year-on-year change?
Over the past year, AZN quarterly accounts receivable has changed by +$579.00 M (+5.12%)